Eiger BioPharmaceuticals, Inc. Stock News

U.S. stocks traded lower this morning, with the Dow Jones dropping over 100 points on Tuesday. All the three major indices recorded their third weekly loss in a row, with the Dow dropping around 3%, a

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q2 2022 Earnings Conference Call August 4, 2022 4:30 PM ET Company Participants Sarah Mathieson - SVP, Corporate Affairs David Cory - President & CEO Ingr

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 28.17% and 94.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

European Commission granted marketing authorization for Zokinvy (lonafarnib) for the treatment of patients with progeria on July 20, 2022. Results from the phase 3 D-LIVR study using Lonafarnib for th

Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Eiger BioPharmaceuticals (EIGR) have performed compared to their sector so far this year.

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the declin

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President-Corporate Affairs David Cory - Presid

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

A near-term opportunity in hepatitis D virus (HDV) infection with lead asset lonafarnib supports valuation 6x higher than current share price, supported by a recent acquisition in the HDV space.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AbbVie's Rinvoq Gets Label Expansion To Treat Ulcerative Colitis AbbVie, Inc. (NYSE: ABBV) announced 

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to s

Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceuti

The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the